EK
Therapeutic Areas
Pi-Cardia Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ShortCut™ | Coronary obstruction risk in valve‑in‑valve TAVR | Commercial (cleared) |
| ShortCut™ Mitral | LVOT obstruction risk in TMVR | Preclinical |
| Leaflex™ Performer | Calcified aortic stenosis | Preclinical |